Effective treatment of severe COVID-19 patients with tocilizumab

Proceedings of the National Academy of Sciences of the United States of America - Tập 117 Số 20 - Trang 10970-10975 - 2020
Xiaoling Xu1, Mingfeng Han2, Tiantian Li1, Sun Wei2, Dongsheng Wang1, Binqing Fu3,4, Yonggang Zhou3,4, Xiaohu Zheng3,4, Yun Yang5, Xiuyong Li6, Xiao‐Hua Zhang2, Aijun Pan5, Haiming Wei3,4
1Respiratory and Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui 230000, People’s Republic of China;
2Respiratory and Critical Care Medicine, Anhui Fuyang Second People’s Hospital, Fuyang, Anhui 230000, People’s Republic of China;
3Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei, Anhui 230000, People’s Republic of China;
4Institute of Immunology and the Chinese Academy of Sciences (CAS) Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei, Anhui 230000, People’s Republic of China;
5Intensive Care Unit, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui 230000, People’s Republic of China;
6Hemodialysis Center, Anhui Fuyang Second People’s Hospital, Fuyang, Anhui 236000, People’s Republic of China

Tóm tắt

Significance In patients with coronavirus disease 2019, a large number of T lymphocytes and mononuclear macrophages are activated, producing cytokines such as interleukin-6 (IL-6), which bind to the IL-6 receptor on the target cells, causing the cytokine storm and severe inflammatory responses in lungs and other tissues and organs. Tocilizumab, as a recombinant humanized anti-human IL-6 receptor monoclonal antibody, can bind to the IL-6 receptor with high affinity, thus preventing IL-6 itself from binding to its receptor, rendering it incapable of immune damage to target cells, and alleviating the inflammatory responses.

Từ khóa


Tài liệu tham khảo

10.1371/journal.ppat.1006698

10.1073/pnas.0409608102

10.1016/S1473-3099(13)70690-X

A. E. Gorbalenya . Severe acute respiratory syndrome-related coronavirus: The species and its viruses—a statement of the Coronavirus Study Group. https://doi.org/10.1101/2020.02.07.937862 (11 February 2020).

World Health Organization WHO Director-General’s remarks at the media briefing on 2019-nCoV (2020). https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. Accessed 11 February 2020.

10.1016/S0140-6736(20)30154-9

10.1016/S0140-6736(20)30211-7

D. Wang ., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, e201585 (2020).

10.1016/S0140-6736(20)30183-5

10.1016/S2213-2600(20)30079-5

10.1016/j.micinf.2012.10.008

10.1099/vir.0.055533-0

10.1016/S2213-2600(20)30076-X

Y. Zhou ., Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl. Sci. Rev., nwaa041 (2020).

10.1016/j.smim.2013.12.002

10.1016/j.cyto.2014.05.024

10.1172/JCI57158

10.1016/j.berh.2012.01.001

10.1016/S0140-6736(08)60454-7

10.1016/S0140-6736(13)60250-0

10.1097/CJI.0000000000000160

Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (7th Interim Edition). China NHCOTPSRO. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf. Accessed 3 March 2020.

Thông tin
Thông tin xuất bản

Proceedings of the National Academy of Sciences of the United States of America

Tập 117 Số 20

10970-10975

Thông tin tác giả